Rania M. Mogawer

Dr. Rania M. Mogawer

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2021 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Closed access
PDF file
SESamia M. Esmat
Samia M. Esmat
MEMedhat El‐Mofty
Medhat El‐Mofty
HRH. Rasheed
H. Rasheed
WMWedad Z. Mostafa
Wedad Z. Mostafa
TATag S. Anbar
Tag S. Anbar
RMRania M. Mogawer
Rania M. Mogawer

25 October 2022 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
SISarah Ibrahim
Sarah Ibrahim
SESamar El‐Tahlawi
Samar El‐Tahlawi
RMRania M. Mogawer
Rania M. Mogawer
MAMervat El Ansary
Mervat El Ansary
SESamia Esmat
Samia Esmat
MEMarwa El‐Hawary
Marwa El‐Hawary

25 May 2023 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
DHDalia M. Abdel Halim
Dalia M. Abdel Halim
AFAhmad Fekry
Ahmad Fekry
RMRania M. Mogawer
Rania M. Mogawer

31 July 2023 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
RYRanda Youssef
Randa Youssef
NENourhan Emad
Nourhan Emad
RMRania M. Mogawer
Rania M. Mogawer
Introduction: There are diverse assessment tools for vitiligo, with no standardized approach that helps unify treatment outcome measures. Thus, comparing different treatment modalities and developing evidence-based recommendations for vitiligo management has been quite challenging. Objectives: We compared the most commonly used tools assessing both vitiligo activity and extent, namely, Vitiligo Disease Activity Score (VIDA) and Vitiligo Area and Severity Index (VASI) score to their newly developed counterparts, namely, Vitiligo Extent Score Plus score (VES plus) and Vitiligo Signs of Activity score (VSAS), to provide insights that would help set recommendations for a unified outcome assessment protocol for vitiligo patients. Methods: Thirty-six active non-segmental vitiligo cases were recruited, 30 of whom completed 48 sessions of narrow band ultraviolet B (NB-UVB). Patients were assessed for both extent and activity both before and after treatment with NB-UVB. Scores were correlated. Additionally, VES plus was assessed for its reliability in comparison to VASI score. Results: Both extent (VASI and VES plus) and activity scores (VIDA and VSAS) showed significant improvement following treatment. Additionally, VES plus and VASI were positively correlating both before and after treatment as well as their percent change. Furthermore, VES plus proved as reliable as VASI. Regarding activity scores, total, hypochromic and Koebner VSAS only correlated with VIDA following treatment. Confetti VSAS neither correlated with VIDA before nor after treatment. Conclusions: VES plus and VASI scores have proven of comparable reliability. While examination-based VSAS score comes as an additive tool to the history-based VIDA score.

3 October 2021 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
MEMarwa El‐Hawary
Marwa El‐Hawary
SESamar El‐Tahlawi
Samar El‐Tahlawi
SISarah Ibrahim
Sarah Ibrahim
MAMervat El Ansary
Mervat El Ansary
RMRania M. Mogawer
Rania M. Mogawer

3 January 2024 in Archives of Dermatological Research
Verified
Journal Article
Open access
PDF file
RMRania M. Mogawer
Rania M. Mogawer
MFMarwa Mohamed Fawzy
Marwa Mohamed Fawzy
AMAhmed Mourad
Ahmed Mourad
HAHeba Ahmed
Heba Ahmed
MNMaha Nasr
Maha Nasr
VHVanessa Hafez
Vanessa Hafez
Background: A myriad of therapeutic modalities for alopecia areata are available; however, none is of high level of evidence, creating an immense need for the evaluation of other treatment modalities, of which topical sodium valproate is of potential role via proposed decrease in beta-catenin breakdown, despite its well-known side effect of hair fall as an oral therapy. Objective: Evaluating the efficacy and the safety of sodium valproate (SV)-loaded nanospanlastics, in comparison to topical corticosteroids, this is the currently available gold standard topical treatment for patchy AA. Methodology: A total of 66 patients with patchy AA were randomly assigned to receive either topical mometasone furoate lotion or topical SV applied twice daily to all patches except a control patch, which was left untreated. Clinical, trichoscopic and biochemical assessments of beta-catenin tissue levels and Axin-2 gene expression were carried out at baseline and after 3 months. Results: Both therapeutic modalities were comparable. Potential efficacy was highlighted by significant improvement in the representative patch, the largest treated patch, to the control patch, the smallest untreated patch in both steroid and valproate groups (p = 0.027, 0.003 respectively). Both beta-catenin levels and Axin-2 gene expression were reduced after treatment, pointing to the inhibitory effect of dominating uncontrolled inflammatory milieu. Baseline beta-catenin was found to significantly negatively correlate with improvement in the representative patch in patients with baseline level above 0.42 ng/ml (p = − 0.042). Conclusion: Both topical SV and steroids are of comparable modest efficacy. Thus, further evaluation of SV is due in combination with intralesional steroids and other anti-inflammatory treatment modalities, together with developing individualized approaches based on baseline beta-catenin level. ClinicalTrials.gov Identifier: NCT05017454, https://clinicaltrials.gov/ct2/show/NCT05017454.